Serum Resistin and Insulin-Like Growth Factor-1 Levels in Patients with Hypothyroidism and Hyperthyroidism

Table 2

Comparisons of laboratory findings and demographic characteristics of 4 subgroups of patients and healthy control groups.

Parameters	Hypothyroid; (𝑛=15); Mean ± SD; Median; (min-max)	Subclinically hypothyroid; (𝑛=16); Mean ± SD; Median; (min-max)	Hyperthyroid; (𝑛=15); Mean ± SD; Median; (min-max)	Subclinically hyperthyroid; (𝑛=15); Mean ± SD; Median; (min-max)	Control group; (𝑛=17); Mean ± SD; Median; (min-max)
Age (year)	46.53 ± 13.98	49.06 ± 12.98	40.40 ± 17.36; 36 (22–79)	46.47 ± 13.66	37 ± 12.53; 34 (22–72)
T-Chol (mg/dL)	254.27 ± 63.78^α*	217.19 ± 44.6^£	146.47 ± 33.69	178.67 ± 44.4^$	178.41 ± 31.64
HDL-Chol (mg/dL)	56.53 ± 11.75	56.69 ± 15.16	51.53 ± 14.0	52.8 ± 9.06	59.65 ± 14.11
LDL-Chol (mg/dL)	163.9 ± 53.91^α$*	125.69 ± 35.42^£	78.27 ± 22.37	101.53 ± 37.06	100.24 ± 26.88
AST (U/L)	51.6 ± 58.31*; 26 (16–213)	32.19 ± 29.76; 22.5 (16–136)	23.2 ± 7.8	23.67 ± 7.9; 20 (16–40)	19.06 ± 4.46; 18 (15–34)
ALT (U/L)	46.47 ± 56.83; 22 (5–204)	41.06 ± 61.75; 21 (9–265)	26.9 ± 9.6	22.0 ± 10.46	19.12 ± 9.76; 17 (7–50)
TSH (µIU/mL)	94.4 ± 89.97^α$*; 65.19 (9.410–306.3)	10.02 ± 5.31^£; 7.67 (5.63–24.96)	0.05 ± 0.06^≠; 0.02 (0.015–0.22)	0.13 ± 0.10^€; 0.1 (0.015–0.270)	2.10 ± 1.26
fT4 (ng/dL)	0.33 ± 0.14^α$*	0.73 ± 0.08^£	3.08 ± 0.88^≠	1.07 ± 0.28	0.83 ± 0.10; 0.81 (0.73–1.03)
Resistin (ng/mL)	13.6 ± 6.25	11.76 ± 5.89; 11.35 (5.72–30.32)	9.51 ± 5.48; 8.66 (4.1–24.76)	14.88 ± 7.73^#	8.45 ± 2.90
IGF-I (ng/mL)	123.7 ± 44.03^*†	111.11 ± 59.35^€; 85.95 (58.8–241)	143.73 ± 54.39	166.6 ± 47.87; 148 (114–243)	184 ± 49.73

𝑃<0.05; ^#: subclinically hyperthyroid and control; *: hypothyroid and control; ^€: subclinically hyperthyroid and subclinically hypothyroid; ^†: subclinically hypothyroid and control; ^α: hyperthyroid and hypothyroid; ^£: hyperthyroid and subclinically hypothyroid; ^$: hypothyroid and subclinically hyperthyroid; ^≠: hyperthyroid and control.